NEWRON PHARMACEUTICALS SPA
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.newron.com
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 26
- Registration Number
- NCT01113320
- Locations
- 🇦🇹
Medical University Innsbruck, Dept. of Neurology, Innsbruck, Austria
🇫🇷Hôpital Roger Sallengro, Lille, France
🇦🇹Medical University Graz, Klinische Abteilung für Spezielle Neurologie, Graz, Austria
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 507
- Registration Number
- NCT01028586
- Locations
- 🇨🇭
Enquire Central Contact, Geneva, Switzerland
A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
- First Posted Date
- 2009-12-07
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 24
- Registration Number
- NCT01027169
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 24
- Registration Number
- NCT01026428
- Locations
- 🇮🇹
Research Site, Roma, Italy
Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 411
- Registration Number
- NCT01019824
- Locations
- 🇬🇧
Parexel, London, England, United Kingdom
Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 964
- Registration Number
- NCT00865579
- Locations
- 🇷🇴
Research Site, Timis, Romania
Phase II Dose Titration Study in Patients With Neuropathic Pain
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 272
- Registration Number
- NCT00736151
- Locations
- 🇦🇹
Universitatsklinik Fur Neurologie, Innsbruck, Austria
🇨🇿Fakultni nemocnice Brno, Brno-Bhunice, Czech Republic
🇨🇿Fakultni Thomayerova nemocnices poliklinikou, Praha, Czech Republic
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 227
- Registration Number
- NCT00642889
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 269
- Registration Number
- NCT00643045
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 549
- Registration Number
- NCT00627640
- Locations
- 🇭🇺
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary
🇭🇺SOTE Neurlogia, Budapest, Hungary
🇮🇳Nizam's Institute of Medical Sciences, Hyderabad, Andh Prad, India
© Copyright 2024. All Rights Reserved by MedPath